A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis

Trial Profile

A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms IMPROVE
  • Sponsors Merck Serono
  • Most Recent Events

    • 20 Apr 2012 Data will be presented at the American Academy of Neurology's 64th Annual Meeting (AAN) [poster P02.089], according to a Merck Serono media release.
    • 15 Jan 2012 Results published in the Journal of the Neurological Sciences.
    • 12 Sep 2009 Results reported at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top